More Herceptin Biosimilars Move In, But Roche Thinks It Can Stand Its Ground

 
• By Lucie Ellis-Taitt
conveyer
More Herceptin Biosimilars Line Up For Assessment In Europe, US and Japan

More from Clinical Trials

More from R&D